IS8503A - Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar - Google Patents

Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar

Info

Publication number
IS8503A
IS8503A IS8503A IS8503A IS8503A IS 8503 A IS8503 A IS 8503A IS 8503 A IS8503 A IS 8503A IS 8503 A IS8503 A IS 8503A IS 8503 A IS8503 A IS 8503A
Authority
IS
Iceland
Prior art keywords
cannabinonide
azate
receptor antagonists
formula
cyclic heterocycles
Prior art date
Application number
IS8503A
Other languages
English (en)
Inventor
Yu Guixue
William R Ewing
Amarendra B Mikkilineni
Pendri Annapurna
Bruce A Ellsworth
Philip M Sher
Gerritz Samuel
Sun Chongqing
Murugesan Natesan
Wu Ximao
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IS8503A publication Critical patent/IS8503A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
IS8503A 2003-12-19 2006-06-08 Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar IS8503A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53145103P 2003-12-19 2003-12-19
PCT/US2004/042878 WO2005063762A1 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators
US11/016,198 US7816357B2 (en) 2003-12-19 2004-12-17 Azabicyclic heterocycles as cannabinoid receptor modulators

Publications (1)

Publication Number Publication Date
IS8503A true IS8503A (is) 2006-06-08

Family

ID=34742367

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8503A IS8503A (is) 2003-12-19 2006-06-08 Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar

Country Status (20)

Country Link
US (1) US7816357B2 (is)
EP (1) EP1697371B1 (is)
JP (1) JP2007514770A (is)
KR (1) KR20060103265A (is)
AT (1) ATE360631T1 (is)
AU (1) AU2004309368A1 (is)
BR (1) BRPI0417820A (is)
CA (1) CA2550375A1 (is)
CY (1) CY1106679T1 (is)
DE (1) DE602004006166T2 (is)
DK (1) DK1697371T3 (is)
ES (1) ES2284081T3 (is)
HR (1) HRP20070267T3 (is)
IL (1) IL176110A0 (is)
IS (1) IS8503A (is)
NO (1) NO20062691L (is)
PL (1) PL1697371T3 (is)
PT (1) PT1697371E (is)
RU (1) RU2006126123A (is)
WO (1) WO2005063762A1 (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2550375A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
EP1807070A1 (en) * 2004-09-29 2007-07-18 Schering Corporation Combinations of substituted azetidinones and cb1 antagonists
ES2325773T5 (es) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
AU2006322707B2 (en) 2005-12-07 2011-09-15 Sumitomo Chemical Company, Limited Pyridazine compound and use thereof
WO2007080720A1 (ja) 2005-12-07 2007-07-19 Sumitomo Chemical Company, Limited ピリダジン化合物およびその用途
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
WO2007102999A2 (en) * 2006-02-21 2007-09-13 Ampla Pharmaceuticals Inc. Cb1 antagonists and inverse agonists
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
WO2008066845A2 (en) * 2006-11-28 2008-06-05 Ampla Pharmaceuticals Inc. Treatment of metabolic syndrome with norfluoxetine
CN101631789A (zh) 2006-12-14 2010-01-20 百时美施贵宝公司 作为大麻素受体调节剂的氮杂双环杂环
FR2910001B1 (fr) * 2006-12-18 2009-03-20 Sod Conseils Rech Applic Derives d'imidazo, pyrimido et diazepine pyrimidine-dione et leur utilisation comme medicament
AR064962A1 (es) * 2007-01-22 2009-05-06 Syngenta Participations Ag Derivados de piridazina utiles como fungicidas
JP2008222603A (ja) * 2007-03-09 2008-09-25 Institute Of Physical & Chemical Research 神経変性疾患の予防・治療剤
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
DE102008000872A1 (de) 2007-04-11 2008-11-13 Basf Se Fungizide Pyridazine, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen sowie sie enthaltende Mittel
CN105250285B (zh) 2007-04-11 2019-09-06 奥默罗斯公司 预防和治疗成瘾的组合物和方法
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
US20090036426A1 (en) * 2007-07-30 2009-02-05 Ampla Pharmaceuticals Inc. CB1 antagonists and inverse agonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2705708A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
WO2010079241A1 (es) * 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012030165A2 (ko) 2010-08-31 2012-03-08 서울대학교산학협력단 P P A R δ 활성물질의 태자재프로그래밍용도
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012142388A2 (en) * 2011-04-15 2012-10-18 New York University Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders
JP5437525B1 (ja) 2012-12-28 2014-03-12 株式会社ナード研究所 チロシン誘導体およびチロシン誘導体の製造方法
BR112015024116A2 (pt) 2013-03-27 2017-10-24 Hoffmann La Roche marcadores genéticos para prever capacidade de resposta à terapia
CA2937967C (en) * 2014-01-29 2022-07-26 Neuropore Therapies, Inc. Heteroaryl amides as inhibitors of protein aggregation
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994898A (en) 1975-10-16 1976-11-30 E. R. Squibb & Sons, Inc. 1,2,4-Triazolo (4,3-b) pyridazin-3-ones
IT1164198B (it) * 1983-04-28 1987-04-08 Isf Spa Preparazione di un derivato piridazinico farmacologicamente attivo
JPS61106576A (ja) 1984-10-31 1986-05-24 Nippon Soda Co Ltd トリアゾロピリダジン−３−オン誘導体及び製造方法
ATE236904T1 (de) 1996-07-25 2003-04-15 Merck Sharp & Dohme Substituierte triazolo-pyridazin-derivate als liganden von gaba-rezeptoren
AU6003099A (en) * 1998-10-06 2000-04-26 Takeda Chemical Industries Ltd. Fused pyridazine compounds, process for the preparation of the same and uses thereof
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
JP2002205992A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd 二環式トリアゾロン誘導体およびそれを含有する除草剤
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
WO2003007887A2 (en) 2001-07-20 2003-01-30 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
WO2003066061A1 (en) * 2002-02-07 2003-08-14 Pfizer Limited Use of pde5 inhibitors such as sildenafil in the treatment of polycystic ovary syndrome
US7307164B2 (en) * 2002-03-25 2007-12-11 Merck & Co., Inc. β-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7351826B2 (en) 2003-02-19 2008-04-01 Neurogen Corporation Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds
TW200528455A (en) 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
CA2550375A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators

Also Published As

Publication number Publication date
BRPI0417820A (pt) 2007-03-27
EP1697371A1 (en) 2006-09-06
NO20062691L (no) 2006-09-14
IL176110A0 (en) 2006-10-05
HK1095138A1 (en) 2007-04-27
ES2284081T3 (es) 2007-11-01
DE602004006166D1 (de) 2007-06-06
HRP20070267T3 (hr) 2007-08-31
JP2007514770A (ja) 2007-06-07
AU2004309368A1 (en) 2005-07-14
CY1106679T1 (el) 2012-05-23
DK1697371T3 (da) 2007-09-17
CA2550375A1 (en) 2005-07-14
PT1697371E (pt) 2007-08-03
WO2005063762A1 (en) 2005-07-14
US7816357B2 (en) 2010-10-19
ATE360631T1 (de) 2007-05-15
KR20060103265A (ko) 2006-09-28
DE602004006166T2 (de) 2008-01-10
EP1697371B1 (en) 2007-04-25
PL1697371T3 (pl) 2007-09-28
RU2006126123A (ru) 2008-01-27
US20050171110A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
SE0401342D0 (sv) Therapeutic compounds
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
SE0401971D0 (sv) Piperidne derivatives
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
GB0413087D0 (en) Therapeutic compounds
TW200716628A (en) Novel compounds
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0402762D0 (sv) Indazole sulphonamide derivatives
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie
SE0402763D0 (sv) Nitro indazole derivatives
WO2006076569A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076598A3 (en) Bicyclic heterocycles as cannabinoid receptor modulators
SE0401343D0 (sv) Therapeutic compounds: Pyridine N oxide as scaffold